Incorporation of Glycoproteome Detection into Large Scale Unbiased Proteomics Studies Utilizing Nanoparticles
US Human Proteome Organization – Bruce Wilcox, et al.
This poster, presented at USHUPO from Prognomiq describes how Seer’s Proteograph™ nanoparticle technology specifically captures unique proteoforms in the corona formation and allow for comprehensive assessment of the circulating glycoproteome.
Introduction
Challenges in early cancer detection have led to poor survival rates, highlighting the need for early diagnostic test development. Biomarkers measured in liquid biopsies offer a less invasive and accessible strategy for early cancer detection. Analyte degradation and dilution in complex biological matrix limit high specificity and sensitivity measurements, making biomarker discovery from blood a formidable challenge. PrognomiQ has developed a comprehensive multi-omics platform integrating multiple analyte measurements, cutting-edge analytical instrumentation, and novel data-analysis approaches. Deep unbiased proteomics analysis in our platform is facilitated by recent advances in sample preparation (i.e. Seer’s Proteograph Product Suite) coupled with improved mass spectrometry instrument sensitivity and speed. Together they provide the ability to quantify thousands of proteins from human plasma without compromising throughput or reproducibility. Additionally, we discovered that Seer’s Proteograph nanoparticle technology specifically captures unique proteoforms in the corona formation and allow for comprehensive assessment of the circulating glycoproteome.
Discover Seer Technology Access Programs & Services
Easily explore the protein universe with Seer. Our service providers and in-house Seer Technology Access Center (STAC) empower your research, accelerating results and deciphering the proteome at unprecedented depth and scale. Answer biology’s most challenging questions — faster.